6505--Fluticasone/Salmeterol Inh Powder
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
NAC PHARMACEUTICALS (36E797)
Contract Value
Not provided
Codes & Classification
Solicitation Number
36E79726R0009
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents3
The Department of Veterans Affairs (VA), through its National Acquisition Center (NAC) Pharmaceuticals office, has issued a solicitation (Procurement Identifier: 36E79726R0009) for the supply of Fluticasone/Salmeterol Inhalation Powder. This procurement falls under NAICS code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is classified under Product Service Code 6505, indicating a focus on pharmaceutical products.
The primary objective of this solicitation is to secure a reliable source of Fluticasone/Salmeterol Inhalation Powder for use within the VA healthcare system. The intended outcome is to ensure consistent and timely access to this essential medication for veterans under VA care. The amendment associated with this notice addresses a correction in the annual estimates for line item 1 and extends the deadline for receipt of offers, reflecting the VA’s commitment to accuracy and fair competition in its procurement processes.
Key requirements for this opportunity include the ability to manufacture and supply pharmaceutical-grade Fluticasone/Salmeterol Inhalation Powder in accordance with all applicable federal regulations and VA standards. Offerors must demonstrate capacity for consistent production, quality assurance, and timely delivery to meet the VA’s annual demand. The solicitation documents, available via the provided SAM.gov link, contain detailed specifications and submission instructions.
The contracting activity is managed by the NAC Pharmaceuticals office, a federal entity within the Department of Veterans Affairs. The primary point of contact for this solicitation is Nicholas I McGregor, who can be reached at [email protected] for any inquiries related to the procurement.
This is a formal solicitation, and interested contractors should review the attached documents on the SAM.gov opportunity page for comprehensive requirements and submission guidelines. The notice is currently active, with a response deadline set for March 18, 2026, at 19:03. Contractors specializing in pharmaceutical manufacturing, particularly those with experience supplying inhalation therapies, are encouraged to evaluate this opportunity in light of their capabilities and compliance with federal procurement standards.
No specific set-aside requirements or special considerations are indicated in the provided information. Contractors should refer to the solicitation attachments for any additional details regarding eligibility, evaluation criteria, or contract terms that will remain consistent throughout the contract lifecycle.
For further information and to access the solicitation documents, interested parties should visit the official SAM.gov opportunity page at: https://sam.gov/opp/fcb9d301893045bdb3a03db84ebf8983/view.